Merck KGAA Begins Transformation Effort By Closing Geneva Site
This article was originally published in The Pink Sheet Daily
Executive Summary
The efficiency program outlined by the German pharma in February will mean elimination of 500 Merck Serono staff in Switzerland, with another 750 employees being redeployed to Germany, China or the U.S.
You may also be interested in...
Merck Serono Says Partnering Part Of Its Future, Seeks Anti-PD-L1 Deal
Mid-sized German pharma says partnering will be part of its future, as it progresses three key pipeline assets and initiates talks with big pharma players wanting to partner its anti-PD-L1 compound.
Merck Serono Says Partnering Part Of Its Future, Seeks Anti-PD-L1 Deal
Mid-sized German pharma says partnering will be part of its future, as it progresses three key pipeline assets and initiates talks with big pharma players wanting to partner its anti-PD-L1 compound.
Merck KGAA Ramps Up Immuno-Oncology R&D To Close Ground On Rivals
The German company is looking to strengthen its cancer immunotherapy portfolio by establishing a dedicated research unit and increasing business development in the field.